201 related articles for article (PubMed ID: 12730701)
1. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy plus lonidamine in non-small cell lung cancer.
Cionini L
Semin Oncol; 1991 Apr; 18(2 Suppl 4):49-52. PubMed ID: 1851578
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial with and without lonidamine in non-small cell lung cancer.
Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
6. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
7. The combined use of radiation therapy and lonidamine in the treatment of brain metastases.
DeAngelis LM; Currie VE; Kim JH; Krol G; O'Hehir MA; Farag FM; Young CW; Posner JB
J Neurooncol; 1989 Sep; 7(3):241-7. PubMed ID: 2677257
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer.
Scarantino CW; McCunniff AJ; Evans G; Young CW; Paggiarino DA
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(5):999-1004. PubMed ID: 8083102
[TBL] [Abstract][Full Text] [Related]
9. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer.
Gatzemeier U; Toomes H; Picollo R; Christoffel V; Lücker PW; Ulmer J
Arzneimittelforschung; 1991 Apr; 41(4):436-9. PubMed ID: 1650226
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
11. Phase I toxicologic study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.
Scagliotti GV; Gozzelino F; Albera C; Pescetti G
Chemotherapy; 1989; 35(1):64-8. PubMed ID: 2541978
[TBL] [Abstract][Full Text] [Related]
13. Lonidamine in non-small-cell lung cancer: a phase II study.
Contu A; Olmeo NA; Pani P; Deriu A; Ortu S; Paga C
Tumori; 1991 Feb; 77(1):52-5. PubMed ID: 1850177
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Band PR; Maroun J; Pritchard K; Stewart D; Coppin CM; Wilson K; Eisenhauer EA
Cancer Treat Rep; 1986 Nov; 70(11):1305-10. PubMed ID: 3768873
[TBL] [Abstract][Full Text] [Related]
17. Lonidamine versus polychemotherapy in advanced non-small-cell lung cancer. A preliminary analysis.
Giaccone G; Bagatella M; Donadio M; Bonardi G; Maestroni F; Calciati A
Tumori; 1989 Feb; 75(1):43-6. PubMed ID: 2540581
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
Pratesi G; De Cesare M; Zunino F
Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of Lonidamine in patients with advanced malignancy.
Evans WK; Shepherd FA; Mullis B
Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
[TBL] [Abstract][Full Text] [Related]
20. Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer.
Jones AL; Hardy JR; Newell DR; Smith IE
Eur J Cancer; 1991; 27(4):519. PubMed ID: 1851622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
